JHL Biotech and Biolake signed a long-term cooperation strategy agreement on March 2, 2013. Biolake is situated in Wuhan’s East High-Tech Zone and brings together executive offices, culture, entertainment, research and development. Established in 2007, Biolake has since attracted a multitude of investors and is already home to many different innovative companies. JHL Biotech’s monoclonal antibody manufacturing plant will be built under current good manufacturing practices (cGMP) and upon completion, will be the largest facility of its kind in the world.
3 月 12